Health Care [ 12/12 ] | Life Sciences Tools & Services [ 71/74 ]
NASDAQ | Common Stock
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.02 Increased by +81.82% | -0.07 Increased by +71.43% |
| May 20, 24 | -0.08 Increased by +27.27% | -0.02 Decreased by -300.00% |
| Mar 5, 24 | 0.11 Increased by +375.00% | 0.23 Decreased by -52.17% |
| Nov 7, 23 | -0.11 Increased by +21.43% | -0.09 Decreased by -22.22% |
| Aug 7, 23 | -0.11 Increased by 0.00% | -0.12 Increased by +8.33% |
| May 15, 23 | -0.11 Increased by 0.00% | -0.12 Increased by +8.33% |
| Feb 27, 23 | -0.04 Increased by +60.00% | -0.14 Increased by +71.43% |
| Nov 14, 22 | -0.14 Decreased by -100.00% | -0.13 Decreased by -7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 17.13 M Increased by +N/A% | 1.28 M Increased by +112.95% | Increased by +7.45% Decreased by N/A% |
| Jun 30, 24 | 6.70 M Increased by +N/A% | -2.12 M Increased by +77.11% | Decreased by -31.68% Decreased by N/A% |
| Mar 31, 24 | 2.56 M Increased by +N/A% | -7.27 M Increased by +22.19% | Decreased by -283.98% Decreased by N/A% |
| Dec 31, 23 | 33.46 M Increased by +346.12% | 9.71 M Increased by +414.13% | Increased by +29.03% Increased by +170.41% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.85 M Increased by +8.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.28 M Decreased by -13.70% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.34 M Decreased by -2.20% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 7.50 M Increased by +245.60% | -3.09 M Increased by +63.09% | Decreased by -41.23% Decreased by -125.35% |